Osteoporosis Drugs Market to Witness Healthy Growth in Coming Years

Rising prevalence of osteoporosis and surge in geriatric population to drive global osteoporosis drugs market

According to TechSci Research report, “Global Osteoporosis Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Route of Administration (Oral, Injectable, and Others), By Region, Forecast & Opportunities, 2025”, the market is anticipated to grow at a healthy CAGR during the forecast period. The key factors propelling the growth of global osteoporosis drugs market include rising prevalence of osteoporosis and surge in geriatric population around the world as they pose high susceptibility for osteoporosis. Growing adoption of sedentary lifestyle is also impacting bone health and thus, there is a rise in demand for osteoporosis drugs. In addition, increase in osteoporosis cases due to menopause in women is acting as a major growth driver for this market. In men, lifestyle associated factors such as smoking, and alcohol abuse are found to promote osteoporosis. This is further expected to augment the global osteoporosis drugs market through 2025.

Moreover, increasing investment in R&D activities for development of advanced new drug classes are also fueling the market growth. The wide range of pipeline drugs for approval in clinical trials are also expected to provide lucrative growth opportunity for osteoporosis drug manufacturers. However, the market is also prone to some challenges. Several side effects of osteoporosis drugs such as heartburn, nausea, irritable bowel syndrome and ulcers in the stomach are likely to hamper the market growth. Furthermore, the time-taking drug approval process is also anticipated to restrain the global osteoporosis drugs market growth.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “Global Osteoporosis Drugs Market”

https://www.techsciresearch.com/report/osteoporosis-drugs-market/5081.html

The global osteoporosis drugs market is segmented based on drug class, route of administration and region. Based on drug class, the market can be segmented into bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Among them, rank ligand inhibitors are expected to register highest CAGR during the forecast period as they are increasingly being used to treat bone metastasis. They work by acting as a chemoattractant to bone for tumour cells that express its receptor, RANK. 

Based on route of administration, global osteoporosis drugs market can be segmented into oral, injectable, and others. Among them, the oral segment accounted for largest market share in 2019 owing to abundant availability of medications which are taken orally. However, the injectable segment is anticipated to witness fastest growth through 2025 owing to growing need for drugs that exhibit improved bioavailability rapid mode of action.

Major players operating in the global osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited. The companies are undergoing new product development and collaborative research initiatives to increase their share in global osteoporosis drugs market

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5081

Customers can also request for 10% free customization on this report.

“North America dominated the global osteoporosis drugs market in 2019 and is expected to hold its dominance through 2025 owing to rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is anticipated to undergo fastest growth during the forecast period due to thriving life science industry and growing awareness about the benefits of osteoporosis drugs,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Osteoporosis Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Route of Administration (Oral, Injectable, and Others), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of global osteoporosis drugs market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global osteoporosis drugs market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]